Table 1. Monoclonal antibodies used for cancer therapy able to induce, so far, hypersensitivity-associated acute coronary syndromes (ACS) of Kounis type (KS).
| Generic name | Trade name | Coronary syndrome-induced |
|---|---|---|
| -ximabs | ||
| Rituximab | Rituxan®, MabThera® | type II of KS6,7 |
| Cetuximab | Erbitux® | type I of KS10 |
| Brentuximab | Adcetris® | none, so far |
| -zumabs | ||
| Alemtuzumab | Campath-1H® | type I of KS11 |
| Bevacizumab | Avastin® | ACS12–14 |
| Trastuzumab | Herceptin® | ACS15,16 |
| Ranibizumab | Lucentis® | ACS14 |
| Pertuzumab | Perjeta® | none, so far |
| Trastuzumab | Kadcyla™ | none, so far |
| -umabs | ||
| Denosumab | Prolia® Xgeva® | none, so far |
| Ipilimumab | Yervoy® | none, so far |
| Ofatumumab | Arzerra® | none, so far |
| Panitumumab | Vectibix® | none, so far |
| -omabs | ||
| Catumaxomab | Removab® | none, so far |
| Ibritumomab | Zevalin® | none, so far |
| Tositumomab-131I | Bexxar® | none, so far |